Skip to content

Study · Not a test of the peptide alone · 2023

8 results

Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.

Visolyi GÁ, Domján BA, Svébis MM, Péterfi A, Lovász BD, Mészáros S, Horváth VJ, Tabák ÁG

Canadian journal of diabetes22 Mar 2023Cited by 5 (Europe PMC)

PMID36963632 (opens in a new tab)DOI10.1016/j.jcjd.2023.03.002 (opens in a new tab)PepBankPUB-36963632
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

ObjectivesOur aim in this study was to compare the efficacy and safety of commercially available fixed-ratio combinations (FRCs) of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and basal insulins by a network meta-analysis of randomized controlled trials (RCTs) of people with type 2 diabetes.MethodsWe present a systematic review and network meta-analyses of RCTs of individuals with type 2 diabetes randomized to FRCs or to their components for ≥24 weeks. All reports were obtained from PubMed or ClinicalTrials.gov up to February 28, 2022. The primary outcome was glycated hemoglobin (A1C) level attained. Secondary outcomes included fasting plasma glucose, change in body weight, and incident hypoglycemia. Treatment effects were estimated as mean difference (MD) and standard error (SE), or as odds ratio (OR) with 95% confidence interval (CI) using the fixed combination of insulin glargine 100 IU/mL and lixisenatide (iGlarLixi) as reference.ResultsWe included 29 RCTs from among the 1,404 articles identified. No direct comparisons between FRCs were found. After excluding some insulin-capped trials to reach model consistency, both FRCs were more efficacious regarding A1C than their components, but no difference between FRCs was found (MD, -0.10%; SE, 0.10%). The effect of the fixed combination of insulin degludec and liraglutide (IDegLira) (MD, -0.47 mmol/L; SE, 0.24 mmol/L) and basal insulins was similar to that of iGlarLixi (reference) on fasting glucose, whereas GLP-1RAs had lower efficacy than iGlarLixi. Weight gain was lower with GLP-1RAs and IDegLira (MD, -0.72 kg; SE, 0.32 kg) than with iGlarLixi (reference) and higher with basal insulins. Incident hypoglycemia (based on different definitions) was least frequent with GLP-1RAs, followed by IDegLira (OR, 0.78; 95% CI, 0.39 to 1.57), iGlarLixi (reference), and basal insulins.ConclusionsFor A1C, both FRCs were more efficacious over their individual components, with similar efficacies of the 2 FRCs.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with type 2 diabetes, both fixed-ratio combinations (IDegLira and iGlarLixi) were more efficacious for A1C than their components.

    In plain wordsIn people with type 2 diabetes, both fixed-ratio insulin and GLP-1 combinations lowered A1C more than their separate components.

    Peptide
    Liraglutide
    Outcome
    DecreaseA1C of fixed-ratio combinations versus their components
    Study

    n: not reported in source

    Comparator
    Components of the combinations
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After excluding some insulin-capped trials to reach model consistency, both FRCs were more efficacious regarding A1C than their components, but no difference between FRCs was found (MD, -0.10%; SE, 0.10%).
    1 context sentence
    Summary · context
    We present a systematic review and network meta-analyses of RCTs of individuals with type 2 diabetes randomized to FRCs or to their components for ≥24 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with type 2 diabetes, no A1C difference was found between the two fixed-ratio combinations (MD -0.10%).

    In plain wordsIn people with type 2 diabetes, the two fixed-ratio combinations did not differ in A1C lowering.

    Peptide
    Liraglutide
    Outcome
    No significant changeA1C difference between the two fixed-ratio combinations
    Study

    n: not reported in source

    Comparator
    iGlarLixi
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    MD
    −0.1%
    FRC comparison

    Source sentences

    Summary
    but no difference between FRCs was found (MD, -0.10%; SE, 0.10%).
    2 context sentences
    Summary · context
    Treatment effects were estimated as mean difference (MD) and standard error (SE), or as odds ratio (OR) with 95% confidence interval (CI) using the fixed combination of insulin glargine 100 IU/mL and lixisenatide (iGlarLixi) as reference.
    Summary · context
    We present a systematic review and network meta-analyses of RCTs of individuals with type 2 diabetes randomized to FRCs or to their components for ≥24 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with type 2 diabetes, the effect of IDegLira on fasting glucose was similar to that of iGlarLixi (MD -0.47 mmol/L).

    In plain wordsIn people with type 2 diabetes, IDegLira lowered fasting glucose about as much as iGlarLixi.

    Peptide
    Liraglutide
    Outcome
    No significant changeFasting plasma glucose, IDegLira versus iGlarLixi
    Study

    n: not reported in source

    Comparator
    iGlarLixi
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    MD
    −0.47 mmol/L
    IDegLira vs iGlarLixi

    Source sentences

    Summary
    The effect of the fixed combination of insulin degludec and liraglutide (IDegLira) (MD, -0.47 mmol/L; SE, 0.24 mmol/L) and basal insulins was similar to that of iGlarLixi (reference) on fasting glucose, whereas GLP-1RAs had lower efficacy than iGlarLixi.
    1 context sentence
    Summary · context
    We present a systematic review and network meta-analyses of RCTs of individuals with type 2 diabetes randomized to FRCs or to their components for ≥24 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with type 2 diabetes, GLP-1 receptor agonists as a class had lower efficacy than iGlarLixi on fasting glucose.

    In plain wordsIn people with type 2 diabetes, GLP-1 drugs as a group lowered fasting glucose less than the fixed combination iGlarLixi.

    Peptide
    Liraglutide
    Outcome
    IncreaseFasting plasma glucose, GLP-1RAs versus iGlarLixi
    Study

    n: not reported in source

    Comparator
    iGlarLixi
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    whereas GLP-1RAs had lower efficacy than iGlarLixi.
    1 context sentence
    Summary · context
    We present a systematic review and network meta-analyses of RCTs of individuals with type 2 diabetes randomized to FRCs or to their components for ≥24 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with type 2 diabetes, weight gain was lower with IDegLira than with iGlarLixi (MD -0.72 kg).

    In plain wordsIn people with type 2 diabetes, IDegLira led to less weight gain than iGlarLixi.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight gain, IDegLira versus iGlarLixi
    Study

    n: not reported in source

    Comparator
    iGlarLixi
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    MD
    −0.72 kg
    IDegLira vs iGlarLixi

    Source sentences

    Summary
    Weight gain was lower with GLP-1RAs and IDegLira (MD, -0.72 kg; SE, 0.32 kg) than with iGlarLixi (reference) and higher with basal insulins.
    1 context sentence
    Summary · context
    We present a systematic review and network meta-analyses of RCTs of individuals with type 2 diabetes randomized to FRCs or to their components for ≥24 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with type 2 diabetes, weight gain was lower with GLP-1 receptor agonists as a class than with iGlarLixi.

    In plain wordsIn people with type 2 diabetes, GLP-1 drugs as a group led to less weight gain than the fixed combination iGlarLixi.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight gain, GLP-1RAs versus iGlarLixi
    Study

    n: not reported in source

    Comparator
    iGlarLixi
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Weight gain was lower with GLP-1RAs and IDegLira (MD, -0.72 kg; SE, 0.32 kg) than with iGlarLixi (reference) and higher with basal insulins.
    1 context sentence
    Summary · context
    We present a systematic review and network meta-analyses of RCTs of individuals with type 2 diabetes randomized to FRCs or to their components for ≥24 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In people with type 2 diabetes, incident hypoglycemia with IDegLira was not clearly different from iGlarLixi (OR 0.78, 95% CI 0.39 to 1.57).

    In plain wordsIn people with type 2 diabetes, low blood sugar events with IDegLira were not clearly different from iGlarLixi, because the range was wide.

    Peptide
    Liraglutide
    Outcome
    No significant changeIncident hypoglycemia, IDegLira versus iGlarLixi
    Study

    n: not reported in source

    Comparator
    iGlarLixi
    Analysis
    Secondary
    Outcome group
    Adverse events · Metabolic and weight

    Measurements

    OR
    0.78 ratio
    IDegLira vs iGlarLixi

    Source sentences

    Summary
    Incident hypoglycemia (based on different definitions) was least frequent with GLP-1RAs, followed by IDegLira (OR, 0.78; 95% CI, 0.39 to 1.57), iGlarLixi (reference), and basal insulins.
    1 context sentence
    Summary · context
    We present a systematic review and network meta-analyses of RCTs of individuals with type 2 diabetes randomized to FRCs or to their components for ≥24 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 08HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In people with type 2 diabetes, incident hypoglycemia was least frequent with GLP-1 receptor agonists as a class.

    In plain wordsIn people with type 2 diabetes, low blood sugar events were least frequent with GLP-1 drugs as a group.

    Peptide
    Liraglutide
    Outcome
    DecreaseIncident hypoglycemia, GLP-1RAs
    Study

    n: not reported in source

    Comparator
    Fixed combinations and basal insulins
    Analysis
    Secondary
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Incident hypoglycemia (based on different definitions) was least frequent with GLP-1RAs, followed by IDegLira (OR, 0.78; 95% CI, 0.39 to 1.57), iGlarLixi (reference), and basal insulins.
    1 context sentence
    Summary · context
    We present a systematic review and network meta-analyses of RCTs of individuals with type 2 diabetes randomized to FRCs or to their components for ≥24 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.